Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Hypersensitivity × BNT162 Vaccine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

COVID-19 2 Severe Acute Respiratory Syndrome 1 Neoplasms 1 Mastocytosis 1 Hypersensitivity 1

Interventions

dexamethasone acetate 1 dexamethasone 21-phosphate 1 asparaginase erwinia chrysanthemi recombinant 1 ZD4054 1 Vincristine 1 Sodium Chloride 1 Rituximab 1 Paclitaxel 1 Methotrexate 1 Doxorubicin 1 Dexrazoxane 1 Dexamethasone 1 Cytarabine 1 Carboplatin 1 Calcium Dobesilate 1 BNT162 Vaccine 1 Asparaginase 1 2019-nCoV Vaccine mRNA-1273 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04761822 2025-08-12

SARS

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 2 Completed

746 enrolled 28 charts

COVID-19, Hypersensitivity, Mastocytosis, Severe Acute Respiratory Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡